The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

Novo Nordisk (NVO) announced that the Food and Drug Administration has approved Ozempic to reduce the risk of kidney disease worsening, kidney ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

The two organizations will produce educational materials about the medicine and its importance for people living with type 1 ...